Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?

Acta Neuropathologica

Volumn 128, Issue 4, 2014, Pages 463-476

  Beekes, Michael ^a   Thomzig, Achim ^a   Schulz Schaeffer, Walter J ^b   Burger, Reinhard ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer s disease; Amyloid (A ); Parkinson s disease; Prion; Prion protein; Risk; Seed; Tau; Transmission; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL; CENTRAL NERVOUS SYSTEM; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; PARKINSON DISEASE; PATHOLOGY; PRION; PROTEIN FOLDING;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; MODELS, MOLECULAR; PARKINSON DISEASE; PRIONS; PROTEIN FOLDING; TAU PROTEINS;

EID: 84930010213     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1324-9     Document Type: Review

References (97)

1. Aguzzi A (2009) Cell biology: beyond the prion principle. Nature 459:924–925
2. Ashe KH, Aguzzi A (2013) Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 7:55–59
3. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ (1994) Induction of beta (A4)-amyloid in primates by injection of Alzheimer’s disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Mol Neurobiol 8:25–39
4. Beekes M, McBride PA, Baldauf E (1998) Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie. J Gen Virol 79:601–607
5. Beekes M, McBride PA (2007) The spread of prions through the body in naturally acquired transmissbile spongiform encephalopathies. FEBS J 264:588–605
6. Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzschmar H (2004) Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci 101:12207–12211
7. Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT (1994) Prior blood transfusions and Alzheimer’s disease. Neurology 44:1159–1160
8. Bolmont T, Clavaguera F, Meyer-Luehmann M et al (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol 171:2012–2020
9. Brown P, Gibbs CJ Jr, Rodgers-Johnson P et al (1994) Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 35:513–529
10. Brown P, Cervenakova L (2005) A prion lexicon (out of control). Lancet 365:122
11. Brown P, Brandel JP, Sato T et al (2012) Iatrogenic Creutzfeldt–Jakob disease, final assessment. Emerg Infect Dis 18:901–907
12. Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11:301–307
13. Castilla J, Saa P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121:195–206
14. Caughey B, Baron GS, Chesebro B, Jeffrey M (2009) Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 78:177–204
15. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey WS (1991) Secondary structure analysis of the scrapie-associated protein PrP 27–30 in water by infrared spectroscopy. Biochemistry 30:7672–7680
16. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333–366
17. Clavaguera F, Bolmont T, Crowther RA et al (2009) Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 11:909–913
18. Clavaguera F, Akatsu H, Fraser G et al (2013) Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci 110:9535–9540
19. Clavaguera F, Hench J, Lavenir I et al (2014) Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol 127:299–301
20. Come JH, Fraser PE, Lansbury PT (1993) A kinetic model for amyloid formation in the prion diseases: importance of seeding. Proc Natl Acad Sci 90:5959–5963
21. Courageot MP, Daude N, Nonno R et al (2008) A cell line infectible by prion strains from different species. J Gen Virol 89:341–347
22. Darby SC, Kan SW, Spooner RJ et al (2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110:815–825
23. Davie CA (2008) A review of Parkinson’s disease. Br Med Bull 86:109–127
24. Daviglus ML, Plassman BL, Pirzada A et al (2011) Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 68:1185–1190
25. Duran-Aniotz C, Morales R, Moreno-Gonzalez I, Hu PP, Soto C (2013) Brains from non-Alzheimer’s individuals containing amyloid deposits accelerate Abeta deposition in vivo. Acta Neuropathol Commun 1:76
26. Eisele YS, Bolmont T, Heikenwalder M et al (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci 106:12926–12931
27. Eisele YS, Obermuller U, Heilbronner G et al (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330:980–982
28. Frost B, Ollesch J, Wille H, Diamond MI (2009) Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem 284:3546–3551
29. Gasset M, Baldwin MA, Lloyd DH et al (1992) Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci 89:10940–10944
30. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521–533
31. Groschup MH, Gretzschel A, Kuczius T (2006) Prion strains. In: Hörnlimann B, Riesner D, Kretzschmar H (eds) Prions in animals and humans. de Gruyter, Berlin, pp 166–183
32. Guest WC, Silverman JM, Pokrishevsky E, O’Neill MA, Grad LI, Cashman NR (2011) Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J Toxicol Environ Health A 74:1433–1459
33. Guo JL, Covell DJ, Daniels JP et al (2013) Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 154:103–117
34. Hansen C, Angot E, Bergstrom AL et al (2011) Alpha-synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 121:715–725
35. Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer’s disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385–407
36. Health Protection Agency (2007) Health protection report (19 January 2007): Fourth case of transfusion-associated variant-CJD infection
37. Heilbronner G, Eisele YS, Langer F et al (2013) Seeded strain-like transmission of beta-amyloid morphotypes in APP transgenic mice. EMBO Rep 14:1017–1022
38. Herva ME, Zibaee S, Fraser G, Barker RA, Goedert M, Spillantini MG (2014) Anti-amyloid compounds inhibit alpha-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). J Biol Chem 289:11897–11905
39. Hörnlimann B, Pauli G, Lemmer K, Beekes M, Mielke M (2006) Prevention of the transmission of prion diseases in healthcare settings. In: Hörnlimann B, Riesner D, Kretzschmar HA (eds) Prions in humans and animals. de Gruyter, Berlin, pp 546–560
40. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci 33:1024–1037
41. Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res 7:656–664
42. Irwin DJ, Abrams JY, Schonberger LB et al (2013) Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurol 70:462–468
43. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532–540
44. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51
45. Kabir ME, Safar JG (2014) Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases. Prion 8:111–116
46. Kane MD, Lipinski WJ, Callahan MJ et al (2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 20:3606–3611
47. Kimberlin RH, Walker CA (1978) Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture. J Gen Virol 39:487–496
48. Klöhn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci 100:11666–11671
49. Kokmen E, Beard CM, O’Brien PC, Kurland LT (1996) Epidemiology of dementia in Rochester, Minnesota. Mayo Clin Proc 71:275–282
50. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 27:1405–1410
51. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U et al (2012) Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep 2:700
52. Lee SJ, Lim HS, Masliah E, Lee HJ (2011) Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 70:339–348
53. Llewelyn CA, Hewitt PE, Knight RS et al (2004) Possible transmission of variant Creutzfeldt–Jakob disease by blood transfusion. Lancet 363:417–421
54. Luk KC, Song C, O’Brien P et al (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci 106:20051–20056
55. Luk KC, Kehm V, Carroll J et al (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–953
56. Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209:975–986
57. Maclean CJ, Baker HF, Ridley RM, Mori H (2000) Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (Callithrix jacchus). J Neural Transm 107:799–814
58. Masuda-Suzukake M, Nonaka T, Hosokawa M et al (2013) Prion-like spreading of pathological alpha-synuclein in brain. Brain 136:1128–1138
59. Meyer-Luehmann M, Coomaraswamy J, Bolmont T et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784
60. Minati L, Edginton T, Bruzzone MG, Giaccone G (2009) Current concepts in Alzheimer’s disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 24:95–121
61. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C (2012) De novo induction of amyloid-β deposition in vivo. Mol Psychiatry 17:1347–1353
62. Mougenot AL, Nicot S, Bencsik A et al (2011) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 33:2225–2228
63. Nonaka T, Watanabe ST, Iwatsubo T, Hasegawa M (2010) Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of neurodegenerative diseases. J Biol Chem 285:34885–34898
64. O’Meara ES, Kukull WA, Schellenberg GD et al (1997) Alzheimer’s disease and history of blood transfusion by apolipoprotein-E genotype. Neuroepidemiology 16:86–93
65. Olanow CW, Perl DP, DeMartino GN, McNaught KS (2004) Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurol 3:496–503
66. Pan KM, Baldwin M, Nguyen J et al (1993) Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci 90:10962–10966
67. Peden A, McCardle L, Head MW et al (2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16:296–304
68. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527–529
69. Plassman BL, Williams JW Jr, Burke JR, Holsinger T, Benjamin S (2010) Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med 153:182–193
70. Prado MA, Baron G (2012) Seeding plaques in Alzheimer’s disease. J Neurochem 120:641–643
71. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136–144
72. Prusiner SB (1998) Prions. Proc Natl Acad Sci 95:13363–13383
73. Prusiner SB (1998) The prion diseases. Brain Pathol 8:499–513
74. Rafalowska J, Barcikowska M, Wen GY, Wisniewski HM (1988) Laminar distribution of neuritic plaques in normal aging, Alzheimer’s disease and Down’s syndrome. Acta Neuropathol 77:21–25
75. Recasens A, Dehay B, Bove J et al (2014) Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 75:351–362
76. Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113:1243–1251
77. Roostaee A, Beaudoin S, Staskevicius A, Roucou X (2013) Aggregation and neurotoxicity of recombinant alpha-synuclein aggregates initiated by dimerization. Mol Neurodegener 8:5
78. Rosen RF, Fritz JJ, Dooyema J et al (2012) Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem 120:660–666
79. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810–813
80. Sanders DW, Kaufman SK, DeVos SL et al (2014) Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron 82:1271–1288
81. Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120:131–143
82. Schulz-Schaeffer WJ (2012) Neurodegeneration in Parkinson disease: moving Lewy bodies out of focus. Neurology 79:2298–2299
83. Schulz-Schaeffer WJ (2014) Morbus Parkinson—a synaptic disorder? Basal Ganglia 4:3–8
84. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189
85. Snowdon DA (1997) Aging and Alzheimer’s disease: lessons from the Nun study. Gerontologist 37:150–156
86. Snowdon DA (2003) Healthy aging and dementia: findings from the Nun study. Ann Intern Med 139:450–454
87. Soto C (2011) Prion hypothesis: the end of the controversy? Trends Biochem Sci 36:151–158
88. Stöhr J, Watts JC, Mensinger ZL et al (2012) Purified and synthetic Alzheimer’s amyloid beta (Abeta) prions. Proc Natl Acad Sci 109:11025–11030
89. Tyas SL, Snowdon DA, Desrosiers MF, Riley KP, Markesbery WR (2007) Healthy ageing in the Nun study: definition and neuropathologic correlates. Age Ageing 36:650–655
90. van Keulen LJ, Vromans ME, van Zijderveld FG (2002) Early and late pathogenesis of natural scrapie infection in sheep. APMIS 110:23–32
91. Volpicelli-Daley LA, Luk KC, Patel TP et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72:57–71
92. Watts JC, Giles K, Oehler A et al (2013) Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci 110:19555–19560
93. Weber P, Giese A, Piening N et al (2006) Cell-free formation of misfolded prion protein with authentic prion infectivity. Proc Natl Acad Sci 103:15818–15823
94. Wemheuer W, Benestad S, Wrede A et al (2009) Similarities between forms of sheep scrapie and Creutzfeldt–Jakob disease are encoded by distinct prion types. Am J Pathol 175:2566–2573
95. Wroe SJ, Pal S, Siddique D et al (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt–Jakob disease associated blood transfusion: a case report. Lancet 368:2061–2067
96. Yamamoto N, Matsuzaki K, Yanagisawa K (2005) Cross-seeding of wild-type and hereditary variant-type amyloid beta-proteins in the presence of gangliosides. J Neurochem 95:1167–1176
97. Zahn R, Liu A, Lührs T et al (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci 97:145–150